MetLife Inc. Shows Resilience Amid Market Challenges
Currently valued at a market cap of $53.9 billion, MetLife, Inc. (MET) is a prominent global financial services company that focuses on insurance, annuities, employee benefits, and asset management. The New York-based firm operates in various regions, including the U.S., Asia, Latin America, Europe, the Middle East, and Africa, catering to both individual and institutional clients.
Financial Overview and Performance Trends
As a company exceeding $10 billion in valuation, MetLife qualifies as a “large-cap” stock. It offers a diverse portfolio of products such as life, dental, disability, accident, health, vision, pet insurance, pension risk transfers, and structured settlements.
Despite a notable 12.2% drop from its 52-week high of $89.05, MetLife shares have declined 2.7% over the past three months. This drop is relatively mild when compared to the broader S&P 500 Index’s ($SPX) decline of 8.7% during the same period.
Long-Term Stock Insights
Looking at longer-term trends, MET is down 4.5% year-to-date (YTD), which reflects a slightly better performance than the SPX’s 5.6% dip. Over the last 52 weeks, however, MetLife shares have shown a 9% gain, surpassing the 8.6% return of the SPX.
Furthermore, MET has largely traded above its 50-day and 200-day moving averages throughout the previous year.
Recent Earnings and Market Response
On February 5, MetLife exceeded Q4 2024 revenue expectations by reporting $19.7 billion. However, the stock fell 1.6% the following day due to an adjusted earnings per share (EPS) of $2.08 that did not meet expectations. Key segments also reported declines, with Group Benefits earnings dropping by 11% to $416 million and Retirement and Income Solutions (RIS) earnings falling by 8% to $386 million, both missing consensus estimates.
Additional challenges emerged with falling adjusted premiums, fees, and revenues in critical markets, including Asia and Latin America. The decline in book value per share as well as total equity, compounded by management’s expectations of ongoing Corporate & Other losses into 2025, likely influenced the negative market sentiment.
Comparative Performance and Analyst Outlook
When comparing performance, MET has underperformed against its competitor, Aflac Incorporated (AFL), which has realized a 27.3% gain over the past year and a 2.4% increase YTD.
Despite these challenges, analysts maintain a positive outlook for MetLife. The stock has received a consensus rating of “Strong Buy” from 18 analysts. Currently, MET is trading below the mean price target of $96.69.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. For more information, please view the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
